In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

The new guidance includes updates on diabetes technology use, GLP-1 receptor agonists, liver disease, drinking water, and ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and ...

The American Diabetes Association has released the Standards of Care in Diabetes-2025, the authoritative guide for ...

Today, the American Diabetes Association® released the Standards of Care in Diabetes—2025 (Standards of Care) the gold ...

Opens in a new tab or window The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and dual GIP/GIP-1 receptor agonists for type ...

Both drugs are also known as incretin therapies or, alternatively, GLP-1 agonists. The shortages have ... In making the statement, ADA, which includes physicians, health educators and community ...

Earlier at ADA, Lilly reported phase 2 results with its once-daily oral GLP-1 agonist orforglipron, which achieved a weight reduction of almost 15% at 24 weeks, potentially giving Lilly the option ...

Clinicians and patients should avoid using compounded GLP-1 products that are not FDA-approved, the American Diabetes Association wrote in a guidance statement published Dec. 2 in Diabetes Care. The ...

The American Diabetes Association is advising doctors and patients not to use compounded GLP-1s due to uncertainty about their content, safety, ...